2.1 billion euros, more than 500 jobs. The Danish pharmaceutical company Novo Nordisk announced this Thursday a major investment plan for its factory located in Chartres, the largest ever made in France in the healthcare sector.
“We had already chosen to invest in France 60 years ago,” Lars Fruergaard Jørgensen, CEO of Novo Nordisk, told BFM Business. Today it is one of our main sites and we want to continue expanding.”
Two emblematic drugs produced in France?
The group, which celebrated its centenary this year, made its first fortune with insulin, of which it remains the world’s leading producer. Before becoming the most valuable European company on the stock market, thanks to the meteoric growth of global sales of its two star drugs, Ozempic and Wegowy, two anti-obesity treatments.
The general director reported that his company was working on the manufacture of a new generation of these two drugs, which could be manufactured in the French plant. “We are in the final phase of development of a new generation of our flagship products. These drugs can be manufactured at this site,” he assured.
Source: BFM TV
